Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease

Jonatan Wärme¹, Martin O Sundqvist¹, Stefan James^{2

3}, Robin Hofmann⁴

Affiliations

¹ Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
² Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
³ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
⁴ Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. robin.hofmann@ki.se.

Comment

Jonatan Wärme et al. Nat Rev Cardiol. 2024 Aug.

. 2024 Aug;21(8):593.

doi: 10.1038/s41569-024-01028-8.

Jonatan Wärme¹, Martin O Sundqvist¹, Stefan James^{2

3}, Robin Hofmann⁴

¹ Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
² Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
³ Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
⁴ Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. robin.hofmann@ki.se.

No abstract available

Comment in

Reply to 'Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease'.
Talasaz AH, Bikdeli B. Talasaz AH, et al. Nat Rev Cardiol. 2024 Aug;21(8):594-595. doi: 10.1038/s41569-024-01029-7. Nat Rev Cardiol. 2024. PMID: 38698182 No abstract available.

Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.
Talasaz AH, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom JW, Siegal DM, Monreal M, Jimenez D, Vaduganathan M, Castellucci LA, Cuker A, Barnes GD, Connors JM, Secemsky EA, Van Tassell BW, De Caterina R, Kurlander JE, Aminian A, Piazza G, Goldhaber SZ, Moores L, Middeldorp S, Kirtane AJ, Elkind MSV, Angiolillo DJ, Konstantinides S, Lip GYH, Stone GW, Cushman M, Krumholz HM, Mehran R, Bhatt DL, Bikdeli B. Talasaz AH, et al. Nat Rev Cardiol. 2024 Aug;21(8):574-592. doi: 10.1038/s41569-024-01003-3. Epub 2024 Mar 20. Nat Rev Cardiol. 2024. PMID: 38509244 Review.

1. Talasaz, A. H. et al. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-024-01003-3 (2024). - DOI - PubMed
1. Malfertheiner, P. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut https://doi.org/10.1136/gutjnl-2022-327745 (2022). - DOI - PubMed
1. Venerito, M. et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment. Pharmacol. Ther. 47, 1464–1471 (2018). - DOI - PubMed
1. Sarri, G. L., Grigg, S. E. & Yeomans, N. D. Helicobacter pylori and low-dose aspirin ulcer risk: a meta-analysis. J. Gastroenterol. Hepatol. 34, 517–525 (2019). - DOI - PubMed
1. Wärme, J. et al. Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. Am. Heart J. 231, 105–109 (2021). - DOI - PubMed